Budget impact analysis on the introduction of a guideline based hepatitis B and C screening into a routine check-up in the German primary care setting

References

• Poethko-Müller C, Zimmermann R, Hamouda O, et al. Die Seroepidemiologie der Hepatitis A, B und C in Deutschland: Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1) [Epidemiology of hepatitis A, B, and C among adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1)]. Bundesgesundheitsbl. 2013;56:707–715.
   Google Scholar
• Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1 Suppl):S45–S57.
   Web of Science ®Google Scholar
• Stahmeyer JT, Becker H, Heidelberger S, et al. Kosten einer leitliniengerechten Versorgung von Hepatitis-B-Patienten in Deutschland [Costs of guideline-based treatment of hepatitis B patients in Germany]. Z Gastroenterol. 2012;50:745–752.
   PubMedGoogle Scholar
• Stahmeyer JT, Rossol S, Bert F, et al. Kosten einer leitliniengerechten Versorgung von Hepatitis-C-Patienten im Zeitalter Interferon-freier Therapien [Costs of a guideline-based treatment of patients with chronic hepatitis C in the era of interferon-free treatment]. Z Gastroenterol. 2016;54:760–769.
   PubMed Web of Science ®Google Scholar
• Cornberg M, Protzer U, Petersen J, et al. Aktualisierung der S3-Leitlinie zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion: AWMF-Register-Nr.: 021/011 [Prophylaxis, diagnosis and therapy of hepatitis B virus infection]. Z Gastroenterol. 2011;5:871–930.
   Google Scholar
• Wolffram I, Petroff D, Bätz O, et al. Prevalence of elevated ALT values, HBsAg, and anti-HCV in the primary care setting and evaluation of guideline defined hepatitis risk scenarios. J Hepatol. 2015;62:1256–1264.
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Berg T, Buggisch P, et al. Addendum vom 18.02.2015 zur S3-Leitlinie 021/012 “Hepatitis-C-Virus (HCV)-Infektion; Prophylaxe, Diagnostik und Therapie”; 2015.
   Google Scholar
• Wedemeyer H, Duberg AS, Buti M, et al. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat. 2014;21(Suppl. 1):60–89.
   PubMed Web of Science ®Google Scholar
• AWMF. Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus (HCV)-Infektion. Ergebnisse einer “Evidenz”-basierten Konsensuskonferenz der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten und des Kompetenznetzes Hepatitis; 2009.
   Google Scholar
• Hourfar MK, Walch LA, Geusendam G, et al. Sensitivity and specificity of anti-HBc screening assays – which assay is best for blood donor screening? Int J Lab Hematol. 2009;31:649–656.
   PubMed Web of Science ®Google Scholar
• Seignères B, Descamps F, Croise R, et al. Multicenter clinical evaluation of the new 3rd generation assay for detection of antibodies against hepatitis C virus on the VIDAS system. J Clin Virol. 2016;78:20–26.
   PubMed Web of Science ®Google Scholar
• Roulot D, Costes J-L, Buyck J-F, et al. Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years. Gut. 2011;60:977–984.
   PubMed Web of Science ®Google Scholar
• Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529–538.
   PubMed Web of Science ®Google Scholar
• Zentrum für Krebsregisterdaten [Internet]. Prävalenz von Leberkrebs [cited March 2015]. Available from: http://www.krebsdaten.de/Krebs/DE/Datenbankabfrage/datenbankabfrage_stufe1_node.html
   Google Scholar
• Grobe TG, Heller G, Szecsenyi J, et al. Arztreport 2014: Schwerpunkt: Hautkrebs. Vol. 5. Siegburg: Asgard-Verlagsservice GmbH; 2014.
   Google Scholar
• Hüppe D, Zehnter E, Mauss S, et al. Epidemiologie der chronischen Hepatitis C in Deutschland – Eine Analyse von 10326 Hepatitis-C-Virus-Infizierten aus Schwerpunktpraxen und -ambulanzen [Epidemiology of chronic hepatitis C in Germany – an analysis of 10,326 patients in hepatitis centres and outpatient units]. Z Gastroenterol. 2008;46:34–44.
   PubMedGoogle Scholar
• McMahon BJ, Holck P, Bulkow L, et al. Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med. 2001;135:759–768.
   PubMed Web of Science ®Google Scholar
• Robert Koch-Institut. Hepatitis C im Jahr 2014: Zur Situation bei wichtigen Infektionskrankheiten in Deutschland. Epidemiol Bull. 2015;289–302.
   Google Scholar
• Papatheodoridis GV, Manolakopoulos S, Touloumi G, et al. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Gut. 2011;60:1109–1116.
   PubMed Web of Science ®Google Scholar
• El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264–1273.
   PubMed Web of Science ®Google Scholar
• Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825–832.
   PubMed Web of Science ®Google Scholar
• Fischer C, Mauss S, Zehnter E, et al. Epidemiologie und Klinik von Patienten mit chronischer Hepatitis B (CHB) in Deutschland – Ergebnisse einer bundesweiten Querschnittstudie [Epidemiology and clinical characteristics of patients with chronic hepatitis B (CHB) in Germany – results of a Nationwide Cross-Sectional Study]. Z Gastroenterol. 2012;50:22–29.
   PubMedGoogle Scholar
• Xu F, Moorman AC, Tong X, et al. All-cause mortality and progression risks to hepatic decompensation and hepatocellular carcinoma in patients infected with hepatitis C virus. Clin Infect Dis. 2016;62:289–297.
   PubMed Web of Science ®Google Scholar
• Townsend R, McEwan P, Kim R, et al. Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C. Value Health. 2011;14:1068–1077.
   PubMed Web of Science ®Google Scholar
• D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217–231.
   PubMed Web of Science ®Google Scholar
• Weinmann A, Koch S, Niederle IM, et al. Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry. J Clin Gastroenterol. 2014;48:279–289.
   PubMed Web of Science ®Google Scholar
• Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014;11:e1001624.
   PubMed Web of Science ®Google Scholar
• Stahmeyer JT, Rossol S, Liersch S, et al. Cost-effectiveness of treating hepatitis C with Sofosbuvir/Ledipasvir in Germany. PLoS One. 2017;12:e0169401.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–185.
   PubMed Web of Science ®Google Scholar
• Seeff LB. Natural history of hepatitis C. Hepatology. 1997;26:21S–28S.
   PubMed Web of Science ®Google Scholar
• Bellentani S, Tiribelli C, Saccoccio G, et al. Prevalence of chronic liver disease in the general population of Northern Italy: the Dionysos study. Hepatology. 1994;20:1442–1449.
   PubMed Web of Science ®Google Scholar
• Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology. 2001;34:809–816.
   PubMed Web of Science ®Google Scholar
• Ohlen J, Liegl JM, Selmair H. Die Langzeitprognose chronischer Virus B- und Virus C-Hepatitiden [Long-term prognosis of chronic B and C viral hepatitis]. Leber Magen Darm. 1995;25:205–210.
   PubMedGoogle Scholar